Up­dat­ed: FDA ex­plains why it won't pull Jaz­z's ac­cel­er­at­ed ap­proval de­spite a failed con­fir­ma­to­ry tri­al

3 years ago
FDA+

As­traZeneca spot­lights pos­i­tive PhII, PhI­II read­out for a pair of next-gen breast can­cer drugs

3 years ago
R&D

A biotech paused a gene ther­a­py hatched by fam­i­lies. Now they want con­trol

3 years ago
Cell/Gene Tx
In Focus

Glyn Ed­wards takes chair­man role at UK on­colyt­ic virus start­up emerg­ing out of stealth

3 years ago
People
Startups

Up­dat­ed: Con­t­a­m­i­na­tion is­sues lead to FDA warn­ing let­ter for South Car­oli­na man­u­fac­tur­ing fa­cil­i­ty

3 years ago
Pharma
FDA+

What is No­var­tis with­out San­doz? Vas Narasimhan is 'pa­tien­t' as new com­pa­ny takes form

3 years ago
Pharma

Au­rinia ‘can­did’ cam­paign en­cour­ages lu­pus nephri­tis pa­tients to stay cur­rent on doc­tor check­ups

3 years ago
Pharma
Marketing

As­traZeneca's block­buster Fasen­ra fails on one of two PhI­II eosinophilic esophagi­tis tri­al end­points

3 years ago
R&D
Pharma

FDA ap­proves J&J's BC­MA-tar­get­ed bis­pe­cif­ic for mul­ti­ple myelo­ma

3 years ago
Pharma
FDA+

Hal­loween ad­comm post­poned as FDA seeks more Ipsen da­ta on ul­tra rare dis­or­der drug can­di­date

3 years ago
FDA+

FDA rais­es safe­ty ques­tions with GSK's po­ten­tial CKD drug ahead of ad­comm

3 years ago
Pharma
FDA+

Mar­ket­ingRx roundup: Pfiz­er bows Sea­son 2 of ‘Sci­ence Will Win’ pod­cast; Gilead’s Kite spon­sors can­cer light up ...

3 years ago
Pharma
Marketing

The med­ical meta­verse is al­ready here, but what does that mean for phar­ma?

3 years ago
Pharma
Marketing

No­var­tis toss­es more US PD-1 sub­mis­sion plans and an­oth­er an­ti-CD40 drug in­di­ca­tion

3 years ago
R&D

Re­cur­sion dis­creet­ly culls a rare dis­ease pro­gram to fo­cus on can­cer, pulls in $150M pri­vate place­ment

3 years ago
Financing
R&D

In bid to keep it­self afloat, tiny Dif­fu­sion Phar­ma­ceu­ti­cals mulls out-li­cens­ing core tech or com­pa­ny sale

3 years ago
Financing
R&D

CEPI teams up with Ko­re­an vac­cine mak­er in $140M pact to scale up its nascent mR­NA plat­form

3 years ago
Deals

Grit­stone bio se­cures PIPE fi­nanc­ing as it un­veils PhI da­ta for vac­cine can­di­date

3 years ago
Financing
R&D

GSK CEO Em­ma Walm­s­ley trig­gers ex­ec­u­tive team re­vamp as vac­cines chief Con­nor ex­its

3 years ago
People
Pharma

Bio­gen's Q3 rev­enue de­clines 10% as fo­cus shifts to new Alzheimer's and ALS drug can­di­dates

3 years ago
Pharma

Al­to Neu­ro­science con­tin­ues march to­ward the clin­ic with Se­ries B, hop­ing to un­veil da­ta next year

3 years ago
Financing
R&D

Ex-Genen­tech sci­en­tist sen­tenced to six months in prison for steal­ing trade se­crets

3 years ago
People
Pharma

Up­dat­ed: In broad re­treat, GSK's new R&D leader aban­dons NY-ESO plans, pulls plug on cell ther­a­py 2.0 al­liances af­ter ...

3 years ago
Deals
Cell/Gene Tx

PD-L1 pi­o­neer Lieping Chen, Rachel Humphrey spin out new biotech to break down the door on cold tu­mors

3 years ago
Startups
R&D
First page Previous page 439440441442443444445 Next page Last page
A service from the Financial Times